The Air Force has partnered with a private medical company who has developed life-saving technology for the battlefield.
According to Army research, excessive blood loss has reportedly been linked to 90 percent of potentially avoidable deaths from wounds sustained on the battlefield. The Air Force Medical Support Agency is providing technology transition assistance to ReMedX, Inc., to assist with reducing the cost of their wound-treatment invention, XSTAT. This assistance is made possible through the DoD Partnership Intermediary Agreement between the Air Force Research Laboratory and Montana State University/MilTech.
XSTAT was approved for use on the battlefield by the Federal Drug Administration (FDA) in April 2014.
Read more by downloading the full story. You may also contact the AF T3 Program Office for more information by clicking here.